Want to see INMD full AI Analyst Report?
INMD Stock Chart & Stats
$14.93
$0.21(1.38%)
At close: 4:00 PM EDT
$14.93
$0.21(1.38%)
Day’s Range― - ―
52-Week Range$12.72 - $16.67
Previous Close$15.05
Volume688.61K
Average Volume (3M)463.49K
Market Cap
$803.89M
Enterprise Value$371.44M
Total Cash (Recent Filing)$501.12M
Total Debt (Recent Filing)$4.45M
Price to Earnings (P/E)11.2
Beta0.85
Next Earnings
Nov 11, 2026EPS Estimate
0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.25
Shares Outstanding57,544,170
10 Day Avg. Volume411,033
30 Day Avg. Volume463,492
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)1.39
Price to Sales (P/S)2.56
P/FCF Ratio11.26
Enterprise Value/Market Cap0.46
Enterprise Value/Revenue0.99
Enterprise Value/Gross Profit1.30
Enterprise Value/Ebitda4.41
Forecast
1Y Price Target
$15.00Price Target Upside0.47% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)1.3
Revenue Forecast (FY)$370.32M
Bulls Say, Bears Say
Bulls Say
Very Low LeverageAn exceptionally conservative capital structure reduces refinancing risk and preserves flexibility to fund product development, sales initiatives, or shareholder returns. This balance-sheet resilience gives InMode greater capacity to manage operating volatility while continuing to invest in its medical-device platform.
Strong Cash ConversionOperating performance continues to translate into cash, strengthening the quality of reported earnings and supporting internally funded investment. Although free-cash-flow growth has weakened, the close relationship between profit and cash generation remains a durable financial advantage.
Recurring Consumables GrowthGrowth in consumables and service revenue demonstrates that InMode benefits from its installed base beyond initial equipment sales. This recurring component can deepen customer relationships, diversify revenue, and make the business model more resilient as procedure volumes develop.
Bears Say
Stagnant Revenue TrajectoryA flat top line following prior annual declines indicates that demand expansion has slowed and that the installed platform is not currently producing strong company-wide growth. Prolonged stagnation could constrain operating leverage, investment capacity, and future earnings progression.
Margin Compression And Higher CostsHigher operating costs and sales-force restructuring are reducing the conversion of revenue into earnings, while management expects margin pressure to persist. Continued expense intensity could offset the benefits of strong gross margins and keep profitability below earlier peak levels.
Patent Litigation ExposureThe court and ITC proceedings create a structural legal risk around important Morpheus8 products, including possible restrictions on importation or sales. Even though the cases are preliminary and InMode plans to defend them, adverse outcomes could affect revenue and operating continuity.
InMode News
INMD FAQ
What was InMode’s price range in the past 12 months?
InMode lowest stock price was $12.72 and its highest was $16.67 in the past 12 months.
What is InMode’s market cap?
InMode’s market cap is $803.89M.
When is InMode’s upcoming earnings report date?
InMode’s upcoming earnings report date is Nov 11, 2026 which is in 18 days.
How were InMode’s earnings last quarter?
InMode released its earnings results on Aug 05, 2026. The company reported $0.346 earnings per share for the quarter, beating the consensus estimate of $0.332 by $0.014.
Is InMode overvalued?
According to Wall Street analysts InMode’s price is currently Undervalued.
Does InMode pay dividends?
InMode does not currently pay dividends.
What is InMode’s EPS estimate?
InMode’s EPS estimate is 0.32.
How many shares outstanding does InMode have?
InMode has 57,544,170 shares outstanding.
What happened to InMode’s price movement after its last earnings report?
InMode reported an EPS of $0.346 in its last earnings report, beating expectations of $0.332. Following the earnings report the stock price went down -1.041%.
Which hedge fund is a major shareholder of InMode?
Currently, no hedge funds are holding shares in INMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
InMode Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$15.00 (0.47% Upside)
$15.00 (0.47% Upside)
Blogger Sentiment
Bullish
INMD Sentiment 80%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 962.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.75%
12-Months-Change
Fundamentals
Return on Equity
11.80%
Trailing 12-Months
Asset Growth
1.69%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
InMode
InMode Ltd. is a medical technology company that engineers, produces, and commercializes aesthetic medical devices globally, including within the United States. The firm's product portfolio is extensive, covering both less-invasive and non-surgical solutions. A core focus lies in their minimally invasive offerings, which leverage exclusive radiofrequency-assisted lipolysis (RFAL) and deep subdermal fractional radiofrequency technologies. These advanced devices facilitate a range of procedures, such as liposuction with concurrent skin firming, body and facial sculpting, intensive skin resurfacing treatments, and various women's health-related aesthetic interventions. Beyond these, InMode also provides non-invasive medical aesthetic products designed to address numerous cosmetic concerns. These include lasting hair removal, facial skin revitalization, the reduction of wrinkles, cellulite improvement, enhancing overall dermal quality and texture, and treating minor vascular and pigmented skin imperfections. Furthermore, the company develops automated, hands-free medical aesthetic systems for applications like dermal tightening, adipose tissue reduction, and muscular toning. Established in 2008, InMode Ltd. operates from its headquarters in Yokneam, Israel. The company was previously known as Invasix Ltd. before officially changing its name in November 2017.
INMD Stock 12 Month Forecast
Average Price Target
$15.00
▲(0.47% Upside)
Technical Analysis
Conmed
―
Integra Lifesciences
―
Avita Medical
―
Sensus Healthcare
―
Establishment Labs Holdings
―
Ownership Overview
0.19% Insiders
6.28% Mutual Funds
0.49% Other Institutional Investors
89.27% Public Companies and
Individual Investors